Drug interactions of clinical significance for the dermatologist: Recognition and avoidance

American Journal of Clinical Dermatology

Volumn 4, Issue 9, 2003, Pages 623-639

  Shapiro, Lori E ^a,b   Knowles, Sandra R ^a   Shear, Neil H ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALLOPURINOL; ASTEMIZOLE; AZATHIOPRINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAPSONE; DERMATOLOGICAL AGENT; ERYTHROMYCIN; ETRETIN; FLUCONAZOLE; FLUOXETINE; GLYCOPROTEIN P; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PROBENECID; QUININE; RETINOID; RITONAVIR; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DEHYDRATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME METABOLISM; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HUMAN; HYPOPROTEINEMIA; HYPOTENSION; HYPOTHERMIA; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; METABOLIC CLEARANCE RATE; NUTRITION; OBESITY; OUTCOMES RESEARCH; PHARMACOGENETICS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX RATIO; SMOKING; STATISTICAL SIGNIFICANCE; STOMACH EMPTYING;

ANTIFUNGAL AGENTS; CIMETIDINE; CITRUS PARADISI; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; FLUOROQUINOLONES; HISTAMINE H1 ANTAGONISTS; HUMANS; MACROLIDES; PIMOZIDE; PLANT PREPARATIONS; SKIN DISEASES;

EID: 0042236626     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304090-00005     Document Type: Review

References (82)

1. Shapiro LE, Shear NH. Drug interactions: how scared should we be? CMAJ 1999; 161: 1266-7
2. Weideman RA, McKinney WP, Bernstein IH. Predictors of potential drug interactions. Hosp Pharm 1998; 33: 835-40
3. Jankel CA, Gitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-9
4. Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health Syst Pharm 1996; 53: 1416-22
5. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacoepidemiology 1998; 18: 1112-20
6. Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000 Feb; 59 (2): 181-92
7. Hoey J. Drug interactions: who warns the patients [editorial]? CMAJ 1999; 161: 117
8. Shapiro LE, Shear NH. Drug interactions/P450. Curr Probl Dermatol 2001; 13: 141-52
9. du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 2001; 8: 153-61
10. Andersen W, Feingold D. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468-73
11. Del Rosso JQ. Clinically significant drug interactions: recognition and understanding of common mechanisms. Curr Pract Med 1998; 1: 62-4
12. Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001; 40 (9): 631-40
13. Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36 (11): 586-90
14. Hoey J. Postmarketing drug surveillance: what it would take to make it work. CMAJ 2001; 165: 1293
15. Shapiro LE, Singer MI, Shear NH. Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. Curr Opin Dermatol 1997; 4: 25-31
16. Singer MI, Shapiro LE, Shear NH. Cytochrome P450 3A: Interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37: 765-71
17. Anastasio G, Cornell K, Menscer D. Drug interactions: keeping it straight. Am Fam Physician 1997; 56: 883-94
18. Marchbanks C. Drug-drug interactions with fluoroquinolones. Pharmacotherapy 1993; 13: 23-5
19. Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000; 68: 613-6
20. Bodey GP. Azole antifungal drugs. Clin Infect Dis 1992; 14: 5161-9
21. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-50
22. Blum RA, D'Andrea DT, Florentino BM. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755-7
23. Hansten PD. Drug interactions. Drug Interactions Newsletter 1996, 906
24. Abramowicz M, editor. Drug interactions. Med Lett 1999; 41: 61-2
25. Preiss R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther 1998; 36: 3-8
26. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery. J Control Release 1999; 62: 25-31
27. Lown KS, Mao RR, Leicihtman AB, et al. Role of intestinal p-glycoprotein (mdrl) in interpatient variation in the oral bioavailabity of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-60
28. Burkhart CN. Ivermectin: an assessment of its pharmacology, microbiology and safety. J Bet Toxicol 2000; 13: 292-6
29. Watkins. Drug metabolism by cytochromes 450 in the liver and small bowel. Gastroenterol Clin North Am 1996; 21: 511-26
30. Birkett DJ, Mackenzie PI, Veronese ME, et al. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993; 14: 292-4
31. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes. Drug Metab Rev 1997; 29: 413-580
32. Ford N, Sonnichsen D. Clinically significant cytochrome P-450 drug interactions: a comment. Pharmacotherapy 1998; 18: 890-1
33. Kolyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37 (1): 8-19
34. Michalets E. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998; 18: 84-112
35. Park BK, Pirmohamed M, Kitteringham N. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Phamacol Ther 1995; 68: 385-424
36. Abramowicz M, editor. Fexofenadine. Med Lett 1996; 38: 95-6
37. Monahan BP, Ferguson CL, Kelleavy ES, et al. Torsades do pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
38. Honig PK, Worthan DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8
39. Cantilena LR, Sorrels S, Wiley T, et al. Fluconazole alters terfenadine pharmacokietics and electrocardiographic pharmacodynamics [abstract]. Clin Pharmacol Ther 1995; 57: 185
40. Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58 (3): 310-5
41. Abramowicz M, editor. Grapefruit juice interactions with drugs. Med Lett 1995; 37: 73-4
42. Benton R, Honig P, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383-8
43. Abdel-Rahman SM, Gotschall RR, Kaufmann RE, et al. Investigation of terbinafine as a CP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65: 465-72
44. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1999; 32: 70-7
45. Tseng CY, Wang SL, Lai MD, et al. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996; 60: 177-82
46. Kang BC, Yang CQ, Cho HK, et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002; 23 (2): 77-81
47. Kobayashi K, Urashima K, Shimada N, et al. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA expressed systems of the rat. Drug Metab Dispos 2003; 31 (7): 833-6
48. Touchette MA, Chandrasekar PH, Milad MA, et al. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992; 34: 75-8
49. Cadle RM, Zenon III GJ, Rodruguez-Bvarradas MC, et al. Fluconazote induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 292-5
50. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; Suppl. 56: 26-32
51. Ahonen J, Olkkola KT, Takala A, et al. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43 (5): 509-14
52. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 64: 332-41
53. Tailor S, Gupta A, Walder S, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350-2
54. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreased the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445-9
55. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237-48
56. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000; 23 (6): 509-32
57. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interactions: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000-4
58. Gomez D, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-9
59. Shennib H, Auger JL. Diltiazem improves cyclosporine dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transplant 1994; 10: 292-6
60. Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons; 1999 Jan: xxi-xxvii, 39-40, 2406-42, 720a-b
61. Fuhr U. Drug interactions with grapefruit juice. Drug Saf 1998; 18: 251-72
62. Roller L. Drugs and grapefruit juice [letter]. Clin Pharmacol Ther 1998; 1: 87
63. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397-402
64. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit juice constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33
65. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7: 391-6
66. Edwards DJ, Bellevue FH, Woster PM. Identification of 6,7-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-90
67. Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8 (3): 293-308
68. Ernst E. Harmless herbs?: A review of the recent literature. Am J Med 1998; 104: 170-8
69. Bottorf MB. Distinct drug-interaction profiles for statins. Am J Health Syst Pharm 1999; 56: 1019-20
70. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22: 25-8
71. McKindley D, Dufresne R. Current knowledge of the cytochrome p-450 isozyme system: can we predict clinically important drug interactions? Med Health R I 1998; 81: 38-42
72. Hansten PD, Horn JR. Drug interactions newsletter (with quarterly updates): a clinical perspective and analysis of current developments. Vancouver: Applied Therapeutics, 1998
73. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: the pharmacokinetic standpoint. Chemotherapy 2001; 47 Suppl. 3: 24-31; 44-8
74. Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons, 1998 Oct: 91-92, 609a-10, 685d-g, 714a-b
75. Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428-37
76. Flockhart DA, Richard E, Woosley RL, et al. Metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity [abstract]. Clin Pharmacol Ther 1996; 59: 189A
77. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6. Clin Pharmacol Ther 1999; 65: 10-20
78. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73: 539-53
79. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphism of human N-acetyltransferase, cytochrome P450, glutathione-s-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29: 59-124
80. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Jealth syst Pharm 2002; 59 (21): 2061-9
81. Snow J, Gibson L. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 2995; 32: 114-6
82. The Medical Letter®. The Medical Letter® handbook of adverse drug interactions. 2003 edition. The Medical Letter, Inc., New Rochelle (NY), 2003